logo
Share SHARE
FONT-SIZE Plus   Neg

Immunomedics Reveals Study Results For Radioimmunotherapy Of Colorectal Cancer

Biopharmaceutical company Immunomedics Ic (IMMU) Monday revealed that colorectal cancer can be safely, specifically and rapidly targeted with TF2 bispecific antibody and a radiolabeled peptide, with limited toxicity to the patient.

The company stated that TF2 is a bi-specific antibody created using the patented Dock-and-Lock conjugation technology. In addition to targeting the carcinoembryonic antigen expressed by many human cancers, TF2 has been engineered to recognize a small peptide that carries radioactivity. This allows the injection of radioactivity to be separated from the administration of the tumor-targeting bispecific antibody, a concept known as pretargeting.

The company further stated that the study results revealed that pretargeting has the potential advantage of delivering increased radiation dose levels selectively to the tumors while minimizing the body's exposure to radiation's harmful side effects.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While buying interest was somewhat subdued, stocks managed to end Tuesday's trading mostly higher. The gains on the day partly offset the steep drop seen in the previous session, although the major averages remain well off their recent highs. Media and entertainment giant Walt Disney Co. said Tuesday that Christine McCarthy, the company's Treasurer for the past 15 years, will succeed James Rasulo as Chief Financial Officer. New Jersey Governor Chris Christie officially kicked off his campaign for president at an event on Tuesday, joining an already crowded Republican field. Speaking at a rally at his former high school in Livingston, New Jersey, Christie declared he is ready to fight for the people of the United States of America.
comments powered by Disqus
Follow RTT